Biotech Values

[DewDiligence]

…this patent…seems to suffer from one of the defects that Momenta claims the Copaxone patents suffer from: indefiniteness due to the failure to adequately define a key term. Namely the same term of "average molecular weight." Anyone see this differently?

In the Copaxone case, NVS/MNTA’s argument that average molecular weight is not well-defined did not make any headway with Judge Jones, who ruled that the meaning of the term is clear to those practiced in the art. So this is likely not a problem in MNTA’s own patent.